[{"id":"913fa15c-9288-4cf0-a89a-f0851bfabf86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04353375","created_at":"2023-07-06T20:09:42.965Z","updated_at":"2025-02-25T14:51:46.214Z","phase":"Phase 2","brief_title":"Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT04353375","lead_sponsor":"Hutchmed","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-07-06"},{"id":"d4d894ac-2658-4499-8ad7-5be03852e67a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05173142","created_at":"2021-12-29T13:53:45.797Z","updated_at":"2025-02-25T14:52:10.343Z","phase":"Phase 1/2","brief_title":"HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors","source_id_and_acronym":"NCT05173142","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR2 overexpression • FGFR2 expression • FGFR2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • docetaxel • Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr) • fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 01/22/2022","start_date":" 01/22/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-03-08"},{"id":"13fa7fc5-9e27-4fe9-afc8-5f930b506cbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04290325","created_at":"2021-01-18T20:49:08.472Z","updated_at":"2025-02-25T14:51:42.306Z","phase":"Phase 2","brief_title":"HMPL-453 in Advanced Malignant Mesothelioma","source_id_and_acronym":"NCT04290325","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/30/2019","start_date":" 12/30/2019","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 03/17/2023","study_completion_date":" 03/17/2023","last_update_posted":"2020-06-16"},{"id":"43be2725-ea91-441b-9161-069f076f83cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03160833","created_at":"2021-01-18T15:34:57.868Z","updated_at":"2025-02-25T14:50:32.155Z","phase":"Phase 1/2","brief_title":"A Study of HMPL-453 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT03160833","lead_sponsor":"Hutchison Medipharma Limited","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fanregratinib (HMPL-453)"],"overall_status":"Unknown status","enrollment":" Enrollment 33","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2020-02-13"}]